文献速递肿瘤 PET/CT核素与放射性配体治疗

探讨前列腺癌男性中游离DNA水平与PSMA阳性肿瘤体积的关系及预后意义:一项回顾性-前瞻性[68Ga]Ga-PSMA-11 PET/CT研究

Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study.
PubMed 文献 · J Nucl Med · 2024-01-02

研究纳入148例经组织学证实的前列腺癌男性,其中激素敏感性前列腺癌74例(50.0%)、去势抵抗性前列腺癌(CRPC)74例(50.0%),于2019年3月至2021年8月间接受[68Ga]Ga-PSMA-11 PET/CT(184.9 ± 18.9 MBq)及血液采样。结果显示cfDNA浓度与PSMA-TV在总体组(r = 0.16,P = 0.049)和CRPC组(r = 0.31,P = 0.007)呈弱正相关,在激素敏感性前列腺癌患者中无相关性(r = -0.024,P = 0.837)。作者认为cfDNA可能是晚期、侵袭性CRPC的生物标志物,但不能可靠反映总肿瘤负荷或预后。

要点

  • cfDNA浓度与PSMA-TV在总体组(r = 0.16,P = 0.049)和CRPC组(r = 0.31,P = 0.007)呈弱正相关。
  • 激素敏感性前列腺癌患者中cfDNA浓度与PSMA-TV无相关性(r = -0.024,P = 0.837)。
  • 生存结局与PSMA-TV相关(P < 0.0001,P = 0.004),与cfDNA无关(P = 0.174,P = 0.12)。

核心结论

  • 作者认为cfDNA可能是晚期、侵袭性CRPC的生物标志物,但不能可靠反映总肿瘤负荷或预后。
  • 作者认为[68Ga]Ga-PSMA-11 PET/CT可对前列腺癌疾病进展全谱系的肿瘤负荷提供高度精细且具有预后价值的评估。

研究设计与样本

  • 回顾性-前瞻性研究,纳入148例经组织学证实的前列腺癌男性(平均年龄70.7 ± 7.7岁)。
  • 其中激素敏感性前列腺癌74例(50.0%)、CRPC 74例(50.0%),于2019年3月至2021年8月接受[68Ga]Ga-PSMA-11 PET/CT(184.9 ± 18.9 MBq)及血液采样。
  • 采用Spearman系数评估PSMA-TV与cfDNA浓度的相关性,Kruskal-Wallis检验比较PSMA-TV四分位组间cfDNA浓度差异,Log-rank及多因素Cox回归分析评估高、低cfDNA和PSMA-TV水平对总生存的预后意义。

主要发现

  • cfDNA浓度与PSMA-TV在总体组呈弱正相关(r = 0.16,P = 0.049),在CRPC组呈弱正相关(r = 0.31,P = 0.007),在激素敏感性前列腺癌患者中无相关性(r = -0.024,P = 0.837)。
  • CRPC队列中,cfDNA浓度在PSMA-TV第4四分位组与第1四分位组间差异显著(P = 0.002),在第4四分位组与第2四分位组间差异显著(P = 0.016)。
  • Log-rank和Cox回归分析显示,生存结局与PSMA-TV相关(P < 0.0001,P = 0.004),与cfDNA无关(P = 0.174,P = 0.12)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Functional imaging with prostate-specific membrane antigen (PSMA) ligands has emerged as the standard imaging method for prostate cancer (PCA). In parallel, the analysis of blood-derived, cell-free DNA (cfDNA) has been shown to be a promising quantitative biomarker of PCA aggressiveness and patient outcome. This study aimed to evaluate the relationship and prognostic value of cfDNA concentrations and the PSMA-positive tumor volume (PSMA-TV) in men with PCA undergoing [68Ga]Ga-PSMA-11 PET/CT imaging. Methods: We recruited 148 men with histologically proven PCA (mean age, 70.7 ± 7.7 y) who underwent [68Ga]Ga-PSMA-11 PET/CT (184.9 ± 18.9 MBq) and blood sampling between March 2019 and August 2021. Among these, 74 (50.0%) had hormone-sensitive PCA and 74 (50.0%) had castration-resistant PCA (CRPC). All patients provided written informed consent before blood sample collection and imaging. The cfDNA was extracted and quantified, and PSMA-expressing tumor lesions were delineated to extract the PSMA-TVs. The Spearman coefficient assessed correlations between PSMA-TV and cfDNA concentrations and cfDNA's relation with clinical parameters. The Kruskal-Wallis test examined the mean cfDNA concentration differences based on PSMA-TV quartiles for significantly correlated patient groups. Log-rank and multivariate Cox regression analyses evaluated the prognostic significance of high and low cfDNA and PSMA-TV levels for overall survival. Results: Weak positive correlations were found between cfDNA concentration and PSMA-TV in the overall group (r = 0.16, P = 0.049) and the CRPC group (r = 0.31, P = 0.007) but not in hormone-sensitive PCA patients (r = -0.024, P = 0.837). In the CRPC cohort, cfDNA concentrations significantly differed between PSMA-TV quartiles 4 and 1 (P = 0.002) and between quartiles 4 and 2 (P = 0.016). Survival outcomes were associated with PSMA-TV (P < 0.0001, P = 0.004) but not cfDNA (P = 0.174, P = 0.12), as per the log-rank and Cox regression analysis. Conclusion: These findings suggest that cfDNA might serve as a biomarker of advanced, aggressive CRPC but does not reliably reflect total tumor burden or prognosis. In comparison, [68Ga]Ga-PSMA-11 PET/CT provides a highly granular and prognostic assessment of tumor burden across the spectrum of PCA disease progression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kluge K, Einspieler H, Haberl D, et al. Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study. J Nucl Med. 2024. PMID: 38050125. doi:10.2967/jnumed.123.266158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。